Physician profile
Jayleen Chen
NPI 1295059046
$2,389.56
in general payments reported to CMS, 2019-2025
9 companies · $664 in 2025
The $664 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2022: $175 · 2023: $454 · 2024: $867 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,067.62 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $690.42 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $234.33 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $180.82 | 2023-2025 | Auvelity |
| Allergan, INC. | $107.08 | 2019 | |
| Ironshore Pharmaceuticals INC. | $51.17 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $23.11 | 2023 | Trintellix |
| Amgen INC. | $21.86 | 2024 | Krystexxa |
| Neurocrine Biosciences, INC. | $13.15 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayleen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.